INTRODUCTION
Therapy with the CD20 antibody rituximab has, despite limited single agent activity, significantly improved the treatment of B-cell Non-Hodgkin's lymphomas, [1] [2] [3] [4] [5] particularly in combination with chemotherapy. 4, [6] [7] [8] However, despite the efficacy of chemoimmunotherapy, certain patients relapse after an initial response. Thus, there is still a need for novel treatment strategies or optimized CD20-targeting approaches. 1 CD20 antibodies mediate anti-tumor activity via various mechanisms. 1, [9] [10] [11] [12] Rituximab-like type I CD20 antibodies efficiently trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) but only moderately induce direct cell death when crosslinked. Type II CD20 antibodies (for example, tositumomab), owing to a unique binding mode, effectively trigger direct cell death but do not efficiently promote CDC. 1, 13 The contributions of the different potential effector mechanisms that are active in vivo in patients are not yet fully understood.
14 Animal models suggest a critical role for Fc-mediated killing. Rituximab loses its therapeutic activity in C1q knockout mice, suggesting CDC as an important effector mechanism in vivo. 15 Furthermore, the critical role of the interaction of the Fc part and Fc receptor (FcR) has been demonstrated for rituximab and other therapeutic antibodies in several animal models. [16] [17] [18] Recently, in a novel transgenic mouse model in which the common g-chain was mutated to prevent FcR signaling, type I CD20 antibodies were shown to lose anti-tumor activity. 19 These data suggested ADCC as an essential mechanism of action for CD20 antibodies.
The most direct evidence for the importance of FcR-mediated effector cell recruitment in humans was derived from analysis of FcR polymorphisms in patients treated with rituximab or trastuzumab. 20, 21 In these patients, the homozygous expression of the FcgRIIIa-V158 (CD16a-V158) variant was correlated with improved response rates and prolonged overall survival. The CD16a-V158 allelic variant binds to human IgG1 with higher affinity than the CD16a-F158 variant, and recent data suggested that NK cells in patients with the homozygous CD16a-V158 polymorphism are more efficiently activated after rituximab infusion, indicating that efficient effector cell recruitment is beneficial for the therapeutic activity of monoclonal antibodies. 22, 23 Consequently, strategies to enhance selected mechanisms of CD20 antibodies have been developed, 24 including fully human CD20 antibodies targeting unique CD20 epitopes with potent CDC activity. 25, 26 Enhancing effector cell recruitment may represent another strategy to optimize the therapeutic potential of CD20 antibodies. 27 Fc-glyco-and Fc-protein-engineered IgG1 antibodies optimized for enhanced CD16a binding are most advanced in clinical development 28, 29 as represented by GA101, a humanized type II glyco-engineered CD20 antibody. 30 Using bispecific antibodies that engage CD20 on tumor cells and CD16 expressed on NK cells and macrophages may represent an interesting strategy to redirect FcR expressing immune effector cells. In several models targeting other antigens, CD16-directed bispecific antibodies were demonstrated to potently trigger lysis 1 of target cells. 31 Binding affinity and avidity for the target antigen have been demonstrated as important parameters for efficient lytic activity of bispecific antibodies, suggesting that bivalent high avidity binding to the target antigen is beneficial. 32, 33 Only limited data for the testing of CD16-directed bispecific antibodies in animal models are available. The complexity of having either transgenic animals expressing the human target antigen and human CD16 or animal models with transplanted human tumor as well as effector cells may contribute to this observation. 34, 35 Clinical experience with CD16-directed bispecific antibodies is also limited. [36] [37] [38] In early studies, major obstacles were the low amounts of bispecific antibody available. Novel bispecific antibody formats may overcome these technical limitations. 39, 40 Already, first clinical studies with bispecific antibodies redirecting T cells highlight the potential of bispecific antibodies that trigger a selected cytotoxic effector cell population. [41] [42] [43] In the current study, a novel bispecific antibody [(CD20) 2 xCD16], bivalently targeting CD20 and monovalently binding CD16 was generated in the tribody format. 40 [(CD20) 2 xCD16] demonstrated potent in vitro activity and was analyzed in humanized mice reconstituted with human CD34-positive cord blood cells.
MATERIALS AND METHODS Antibodies
The human monoclonal antibody 7D8-IgG1 directed against CD20 was provided by Genmab (Utrecht, The Netherlands) and shows in many aspects, characteristics similar to the clinically approved CD20 antibody ofatumumab (Arzerra; Genmab and GlaxoSmithKline (Munich, Germany)). 25 As control IgG1 antibodies rituximab (Rituxan, Roche, Grenzach-Wyhlen, Germany), trastuzumab (Herceptin; Roche) or cetuximab (Erbitux; Merck KGaA, Darmstadt, Germany) were used. Murine CD16 antibody 3G8 (ref. 44) and CD7 antibody TH-69 (ref. 45) were used in blocking experiments.
Culture of eukaryotic cells
Daudi, Raji and BHK-21 cells (American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in RPMI 1640-Glutamax-I medium (Invitrogen, Karlsruhe, Germany), supplemented with 100 mg/ml penicillin, 100 mg/ml streptomycin, 10% fetal calf serum (R10 þ medium). BHK-21 cells, stably transfected with expression constructs coding for the FcR common g-chain and human FcgRIIIa-F158 or FcgRIIIa-V158 cDNAs, were cultured in medium supplemented with 10 mM methotrexate (SigmaAldrich, Munich, Germany) and 500 mg/ml geneticin (Invitrogen) to ensure stable surface expression of FcgRIIIa. SK-BR-3 cells (ATCC) and Lenti-X 293 T cells (Clontech, Mountain View, CA, USA) were cultured in Dulbecco's modified Eagle medium-Glutamax-I medium (Invitrogen), supplemented with 10% fetal calf serum, 100 mg/ml penicillin and 100 mg/ml streptomycin (D10 þ medium).
Bacterial strains and plasmids
Mach1 T1 Phage-resistant Escherichia coli strain (Invitrogen) was used for cloning and amplification of plasmids. Derivatives of the vector pSEC-Tag2 Hygro C (Invitrogen) were used for expression in eukaryotic cells.
Construction of the recombinant bispecific antibody derivatives
The coding sequences for the variable regions of the CD16 antibody (clone 3G8) and for the Ckappa and CH1 domain of human IgG1 were synthesized according to published sequences (Genbank accession: AY173025 (heavy chain) and AY173024 (light chain) by Entelechon GmbH, Regensburg, Germany). During that process, the codon usage was optimized, and sequence optimization to remove potential RNA secondary structures was performed. Linker sequences ( Figure 1a ) and appropriate restriction sites were introduced to allow cloning of scFv-fragments as SfiI-cassettes, as described earlier. 46 Two expression vectors, pSEC-Tag2-HC-CD16-VH and pSEC-Tag2-LC-CD16-VL were cloned to allow eukaryotic expression of the heavy chain and light chain derivative, respectively. ScFv-fragments specific for CD20 (clone 7D8; 25, 26 ) or specific for Her2 (clone 4D5; 47 ) were generated in VL-VH orientation, according to published sequences using standard procedures. 46, 48 Expression and purification of the antibody derivatives Lenti 49 After 9 h, medium was replaced by fresh culture medium. Tissue culture supernatants were collected every 48 h for 6 days. The antibody derivatives were purified from supernatant by two successive steps of affinity chromatography to ensure their heterodimeric structure (Figure 1 ). In the first step, molecules were captured on CaptureSelect Fab kappa affinity matrix (BAC B.V., Naarden, The Netherlands), according to the manufacturer's conditions. Elution fractions were collected and nickelnitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen, Hilden, Germany) were used in the second purification step. The protein was extensively dialysed against phosphate-buffered saline (PBS; Invitrogen) and stored at 4 1C until use. Typical amounts of tribody were in the range of 300-400 mg/l culture supernatant. No efforts were made to optimize production by establishing stably transfected cell lines and high-density cultivation methods.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), immunodetection of proteins and capillary electrophoresis Antibody derivatives were analyzed by SDS-PAGE under reducing and non-reducing conditions, according to standard procedures. Purity and concentrations of the purified proteins were determined by Coomassie staining (colloidal Coomassie brilliant blue G250 solution (Carl Roth GmbH, Karlsruhe, Germany)) or by capillary electrophoresis using an Experion Automated Electrophoresis System (Bio-Rad, Munich, Germany), according to the manufacturer's instructions.
For western blot analysis, proteins were transfered to polyvinylidene difluoride membrane (Bio-Rad). The light and heavy chain derivatives were detected with goat-anti-human-kappa light chain antibody conjugated with horseradish peroxidase (BIOZOL, Eching, Germany) or Penta-His IgG (Qiagen) as primary antibody and secondary goat-anti-mouse antibody coupled to horseradish peroxidase (Dianova, Hamburg, Germany), respectively. Supersignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, Bonn, Germany) was used for chemiluminescence detection and visualization.
Gelfiltration chromatography
Gelfiltration chromatography was performed on an Ä KTA purifier (GE Healthcare) using PBS as running buffer at a constant flow rate of 1 ml/min. 200 mg protein were loaded in a volume of 1 ml on a Superdex 200 10/300 GL column (GE Healthcare, Munich, Germany). Ferritin (440 kDa), human IgG1 (150 kDa), conalbumin (75 kDa) and ribonuclease A (13.7 kDa) were used for calibration. Data were analyzed with Unicorn 5.1 software (GE Healthcare).
Binding analysis of bispecific antibodies
Briefly, 3 Â 10 5 cells were incubated with purified antibody derivatives in PBS supplemented with 1% bovine serum albumin (BSA; Carl Roth GmbH) (FACS-buffer) for 30 min at 4 1C. Cells were washed two times with FACSbuffer. After incubation with 10 mg/ml Penta-His Alexa Fluor 488 conjugated IgG (Qiagen) for 30 min at 4 1C and an additional washing step, cells were analyzed on a flow cytometer (Epics XL; Beckman Coulter, Fullerton, CA, USA).
Fractionation of human blood/ preparation of effector cells Peripheral blood of healthy volunteers was drawn after obtaining written informed consent. For isolation of effector cells, blood was layered over a discontinuous Percoll (Biochrom AG, Berlin, Germany) gradient consisting of 70 and 62% Percoll solutions. After centrifugation, plasma was taken from the surface layer. Mononuclear cells (MNC) were collected at the interface between plasma and Percoll and polymorphonuclear cells (PMN) from the interface between the two Percoll layers. Remaining erythrocytes were removed by hypotonic lysis. Cell viability was tested by trypan blue (Sigma) exclusion and was higher than 95%. NK cells were enriched from the MNC fraction by negative selection using NK-cell isolation Kit (Miltenyi, Bergisch Gladbach, Germany) and MACS technology, following manufacturer's protocols. Purities ranged between 90 to 98% as judged by 2-color CD20-directed tribody targeting lymphoma P Glorius et al flow cytometry using CD16-and CD56-specific antibodies. CD56-positive cells were isolated from MNC of lymphoma patients using CD56 microbeads (Milltenyi). Isolated effector cells were immediately used or cultured overnight at a density of 2 Â 10 6 cells/ml in R10 þ medium. Experiments reported here were approved by the Ethics Committee of the Christian-Albrechts University (Kiel, Germany), in accordance with the Declaration of Helsinki.
Chromium release assay (ADCC and CDC assay)
Chromium release assays were performed as described. 50 A total of 1 Â 10 6 target cells were labeled with 100 mCi
51
Cr for 2 h. Whole blood, plasma, or isolated effector cells and sensitizing antibodies, at indicated concentrations, were added to microtiter plates. Assays were started by adding target cells (50 ml) to a final effector to target (E:T) ratio of 40:1, unless otherwise indicated. After 3 h at 37 1C, 25 ml supernatant of each sample was added to 150 ml OptiPhase Supermix Cocktail (Perkin-Elmer, Waltham, MA, USA) and incubated for 15 min at room temperature and continuous shaking. 51 Cr release from triplicates was measured in counts per minute (c.p.m.) in a scintillation counter (1450 LSC & Luminescence Counter, Perkin-Elmer), according to the manufacturer's instructions.
Percentage of cellular cytotoxicity was calculated using the formula '% specific lysis ¼ (experimental c.p.m.-basal c.p.m.)/ (maximal c.p.m.-basal c.p.m.) x 100', with maximal 51 Cr release, determined by adding Triton X-100 (final concentration 1%), and basal release measured in the absence of sensitizing antibodies and effector cells.
B-cell depletion and NK-cell activation in whole blood
A quantity of 125 ml of whole blood, 50 IU/ml heparin or 50 mg/ml lepirudin (Refludan, Pharmion, Hamburg, Germany), sensitizing antibodies and R10 þ medium were added to a final volume of 500 ml. After 24 h at 37 1C in a humidified atmosphere containing 6% CO 2 , depletion of B cells and activation of NK cells was analyzed by flow cytometry. For analyzing B-cell depletion, 150 ml of each sample were stained with a mixture of CD3-IgG-FITC (BD Biosciences, Heidelberg, Germany), CD19-IgG-PE (Beckman Coulter GmbH, Krefeld, Germany) antibodies, Intratect (final concentration 2 mg/ml) (Biotest, Dreieich, Germany) and FACS-buffer. After washing with FACSbuffer, cells were fixed and erythrocytes were removed by adding 700 ml of a mixture of VersaLyse lysing solution and IOTest 3 fixative solution (Beckman Coulter) to the cell pellet. A total of 3 Â 10 4 events were collected on a flow cytometer (FC500; Beckman Coulter). The percentage ] to verify its dimeric structure. Reduced and non-reduced protein samples were analyzed with anti-His-tag and anti-human-kappa antibodies. a-His, anti-His-tag antibody; a-h-kappa, anti-human-kappa antibody; n.r., non-reducing conditions; red., reducing conditions. St, molecular weight marker. Data shown are representative results from one experiment out of at least three experiments that were performed. (e) Gelfiltration analysis of the purified [(CD20) 2 xCD16] tribody was performed to investigate the formation of non-covalently linked higher molecular mass forms of the tribody molecule.
CD20-directed tribody targeting lymphoma P Glorius et al of remaining B cells (CD19 þ /CD3 -) was calculated using the formula '% remaining B cells ¼ (experimental % B cells)/ (maximal % B cells) x 100'.
For analyzing NK-cell activation, 150 ml of each sample were stained with a mixture of CD3-IgG-FITC, CD69-IgG-PE (Beckman Coulter), CD56-IgG-PC7 (Beckman Coulter), Intratect (final concentration 2 mg/ml) and FACS-buffer. Cells were washed as described above. A total of 3 Â 10 4 events were collected and gated for CD56-positive and CD3-negative lymphocytes. Within this population, the amount of activated NK cells was determined by calculating the percentage of CD69-positive cells.
Humanized mice
Human CD34-positive hematopoietic stem cells were isolated from cord blood by density gradient centrifugation, enriched with the CD34 Progenitor Cell Isolation Kit (Miltenyi) and stored at À 80 1C until use. Newborn NOD scid gamma-c À / À mice were irradiated with 1.3 Gy followed by transplantation with 3-5 Â 10 4 hematopoietic stem cells essentially, as described. 51 Fourteen-to-sixteen weeks after transplantation, peripheral blood was analyzed for the presence of human cells. For this, mononuclear cells were obtained by density gradient centrifugation followed by staining with human CD45 and CD16, CD19, CD20, CD33 and CD56 (all from BD-Biosciences) as lineage-specific markers. Experiments were performed in mice containing at least 65% human CD45-positive cells. All experiments were performed according to the German Animal Protection Law with permission from the responsible local authorities.
Statistical analysis
Group data are reported as mean±s.e.m. Differences between groups were analyzed by one-way or two-way ANOVA or paired Student's t-test. Significance was accepted, when the P-value was less than 0.05. Levels of statistical significance are indicated by an asterisk (*) or a number sign (#).
RESULTS

Design and characterization of the bispecific tribody [(CD20) 2 xCD16]
A bispecific antibody was designed in the tribody format for redirecting CD16-positive effector cells against CD20-positive malignant B cells. The heterodimeric molecule consists of a CD16-directed Fab-fragment with a CD20-directed scFv C-terminally fused to both peptide chains (Figures 1a, b) . The tribody was expressed in Lenti-X 293T cells and purified from culture supernatants by two-step affinity chromatography. The purity and integrity was estimated by Coomassie-stained gels, western blot analysis, capillary electrophoresis and gel filtration (Figures 1c-e) . No signs of degradation were detected. Western blot analyses and gel filtration experiments revealed that predominantly a dimeric protein close to the expected mass of 110 kDa was expressed (Figures 1d, e) . Only a minor fraction of higher molecular mass aggregates and co-purified contaminants were detected (Figure 1e) . The secretion/purification of homodimeric molecules was not observed in significant quantities (o1%; data not shown). Two similarly designed molecules [(Her2) 2 xCD16] and [(CD20) 2 xCD89] were produced (data not shown) and served as controls.
Flow cytometric analysis revealed that [(CD20) 2 xCD16] retained the binding specificities of the parental CD16 as well as CD20 antibody (Figure 2a) . Briefly, the tribody reacted with BHK cells stably transfected with the CD16a-F158 or the CD16a-V158 alloform and with CD20-positive Daudi cells, whereas no binding was observed with antigen-negative control cells. Interestingly, no differences in binding affinity to both CD16a alloforms were observed (Figure 2b Figure 1) . This may be explained by a lower CD20-binding affinity of the tribody compared with monoclonal antibodies.
The ability of [(CD20) 2 xCD16] in mediating lysis of Daudi cells, using whole blood as source of effector cells, was investigated (Figure 3a) . [(CD20) 2 xCD16] triggered significant lysis of tumor cells whereas the control molecule [(Her2) 2 xCD16] showed no killing activity. Thus, CD16 binding without CD20 engagement is not sufficient to induce lysis of target cells. To determine which effector cell population was responsible for the observed cytotoxic effect, whole blood was separated into plasma, PMN and MNC. As expected, MNC were identified as the effective cell population, indicating that target cell lysis was mediated by NK cells present in the MNC fraction and expressing the activating CD16a isoform. Interestingly, stronger lysis was observed with [(CD20) 2 xCD16] compared with rituximab ( Figure 3b ). Target cell lysis was observed over a wide range of effector to target (E:T) cell ratios. Even at a low ratio of 2.5:1, significant lysis occurred (Figure 3c ). Because MNC used in these experiments contain only B10% ] could be shown to be CD16-dependent, because ADCC was significantly blocked (B50%) in the presence of the parental CD16 antibody (data not shown). As expected, no complement-mediated lysis was observed using low antibody concentrations (Figure 3b ). At higher antibody concentrations, rituximab significantly triggered CDC, while [(CD20) 2 xCD16] did not mediate this effector mechanism (Figure 3d ). The potential impact of serum, containing high levels of endogenous immunoglobulin, on tribody-mediated effector cell killing was further analyzed. Addition of serum to standard 3 h ADCC assays did not show an impact on ADCC (Figure 3f) . At a lower concentration of 0.16 nM, a significant reduction in activity of 20 and 50% at 24 h and 48 h was observed, respectively. Taken into account that tribodies display in vivo retention half-lives in the range of 6-7 h, these data suggest that the presented tribody molecule is sufficiently stable for in vivo application. 52 In the next set of experiments MNC-mediated ADCC was analyzed in comparison to rituximab. Target cells were killed in a dose-dependent manner with half-maximal lysis at B10 pM concentration (Figure 4a) . In comparison to rituximab, the lytic capacity of the tribody was higher in terms of half-maximal lysis (B9-fold enhancement) and at saturating antibody concentrations (B1.4-fold enhancement). As effector cell lysis mediated by rituximab has been demonstrated to be affected by the CD16a polymorphism at position 158, ADCC experiments with MNC effector cells from an FcgRIIIa V/V or F/F donor were performed. Interestingly, the lytic capacity of [(CD20) 2 xCD16] was stronger than that of rituximab irrespective of the CD16a allotype (Figure 4b ). (Table 1) were consistently killed in the presence of and P14) were isolated. About 10-20% killing was observed with [(CD20) 2 xCD16], indicating that the effector cells of these patients were functionally active and can be triggered by [(CD20) 2 xCD16] (Figures 5d, e) .
Killing of freshly isolated tumor cells Tumor cells of 14 patients with different B-cell malignancies
B-cell depletion and NK-cell activation in whole blood Rituximab, 7D8 as well as [(CD20) 2 xCD16] tribody significantly depleted autologous B cells from an isolated MNC fraction (Supplementary Figure 2) . When B-cell depletion was analyzed in whole blood assays, the [(CD20) 2 xCD16] tribody was more active than rituximab or 7D8 when the complement system was inhibited by adding high concentrations of heparin. Although B50 to 65% of B cells were depleted by the tribody, little reduction was observed with 7D8 and none with rituximab ( Figure 6a ). When lepirudin was used as anti-coagulant, which, in contrast to heparin, does not interfere with complement activation, 53 the bispecific antibody as well as the monoclonal antibodies demonstrated strong B-cell depletion. [(CD20) 2 xCD16] showed more than 60% B-cell depletion at a low antibody concentration of 1 nM. To achieve comparable effects, B10-or 100-fold higher concentrations of 7D8 or rituximab had to be employed, respectively (Figure 6a ; right panels). Interestingly, at an antibody concentration of 100 nM, 7D8 depleted more than 90% of B cells, while [(CD20) 2 xCD16]-mediated depletion was lower (Figure 6a) . Depletion of B cells by the tribody most likely occurred via recruitment of NK cells, because upregulation of CD69 on NK cells and no inhibitory effect of heparin was observed. In addition, this format, owing to its heterodimeric nature and modular design, allows generation of tribodies targeting two different antigens on tumor cells. 40 The concept of replacing one CD20 scFv, by a targeting domain directed against other B-cell expressed antigens, such as CD19, CD22 or CD37, is similar to the idea of other bispecific antibody formats that have been used for dual targeting of tumor cells 32, 54 55, 56 may have inhibited rituximab-and 7D8-mediated effector cell recruitment in this model system. This suggests that high affinity CD16-binding of the tribody evades this inhibitory effect. Although ADCC was the sole effector mechanism triggered by [(CD20) 2 xCD16], in whole blood assays with an active complement system potent B-cell depletion was observed at 100-fold lower concentrations compared with rituximab. Efficient ADCC mediated by the tribody more potently eliminated target cells than rituximab with its combined ADCC, CDC and antiproliferative activity. Tumor cell killing at low antibody concentrations may be especially important for tumor cells that reside at sites where high antibody concentrations may not easily be reached. In addition, efficient B-cell depletion without complement activation may reduce side effects observed during initial infusions of rituximab. 57 The capacity of therapeutic antibodies in triggering effector cell-mediated lysis is affected by the CD16a polymorphism at amino-acid position 158. Individuals homozygous for valine at this position show higher affinity CD16a binding, more efficient antibody-induced NK cell activation in vivo, enhanced cytolytic potential and more favorable clinical response rates. [20] [21] [22] [23] 58 [(CD20) 2 xCD16] bound to CD16a-V158 and CD16a-F158 with roughly the same affinity. Recently, differences in CD16a-V/F binding have been reported for the parental murine CD16 antibody 3G8 (ref. 59) that was used for generating the tribody molecule. This may be explained by different assay conditions, or by the fact that the group of Congy-Jolivet used the murine 3G8 antibody, 59 while a chimeric monovalent Fab-fragment derived from the 3G8 V-regions was analyzed here. Functionally, [(CD20) 2 xCD16] more efficiently triggered ADCC than rituximab irrespective of the CD16a polymorphism, suggesting that a therapy with the tribody molecule may be less compromised by this genetic polymorphism.
Because tumor cells from patients with different lymphomas, including CLL cells that express CD20 at relatively low levels, (Table 1) were killed consistently, the novel tribody may be effective at low antigen densities. Additionally, tumor cell killing was observed also in an autologous setting. Thus, the patient's unstimulated NK cells strongly inhibited by tumor cell-expressed MHC class I molecules, may be activated through a strong triggering signal via CD16a, although to a lesser extent compared with the allogeneic situation when effector cells of healthy donors were used. The observed reduced ADCC potency, although using higher effector-to-target ratios, might be due to MHC class I inhibition of effector cell activation or to a reduced cytotoxic potential of patient-derived effector cells. Therefore, molecules like the presented tribody may be especially interesting in clinical settings with a low tumor load (MRD situation) and high effector cell numbers resulting in high effector-to-target cell ratios. These situations can potentially be realized in post-transplantation settings because NK cells are among the first cell populations that recover. In addition, combinations with adoptively transferred ex vivo expanded NK cells may also represent promising approaches that can be further explored.
Recently, Lim and colleagues demonstrated that Fc-dependent co-engagement of CD32b co-expressed with CD20 on tumor cells via rituximab and other type I CD20 antibodies triggered CD20 internalization thereby potentially negatively affecting CD20-directed therapy. The novel tribody does not bind to CD32b and therefore this negative effect may be less pronounced for this novel tribody. 60 Importantly, the [(CD20) 2 xCD16] tribody effectively reduced B-cell numbers in humanized mice, reconstituted by transplantation of human CD34-positive cord blood cells. In this model, B cells and CD16-positive effector cells developed from the same donor allowing analysis of in vivo B-cell depletion in an autologous setting. This model avoids xeno-transplanted tumor cells with high numbers of allogeneic effector cells or transgenic expression of human target and trigger molecules on murine cells. Our experiments clearly demonstrated that the novel tribody is capable in eliminating autologous B cells in an in vivo setting. Three consecutive injections achieved a reduction of B40 to 50% of B cells. Incomplete B-cell depletion may be due to low E:T ratios detected in the peripheral blood of the transplanted mice (data not shown). Therefore, prolonged injections may be necessary for complete B-cell elimination, as shown for a CD32bxCD16 bispecific antibody. 34 Several studies have demonstrated that single-chain bispecific antibodies in the tandem scFv-format such as blinatumomab display very short in vivo half-lives. 34 Tribodies may due to their higher molecular mass have longer in vivo half-lives than tandem scFvs. This may be advantageous given the need for continuous infusion with recently described bispecific antibody blinatumomab. 41 Nevertheless, because of the lack of a Fc portion tribodies will not be recycled by the FcRn receptor probably resulting in shorter in vivo half-lives compared with monoclonal antibodies. In addition, our in vitro data suggest that prolonged exposure times of this specific tribody molecule to human serum led to reduced ADCC activity. Consequently, the in vivo efficacy of tribody molecules may be further enhanced by engineering their pharmacokinetic properties and serum stability.
In conclusion, the novel bispecific antibody described here displays potent ADCC activity irrespective of the CD16a polymorphism at position 158, is active in a preclinical in vivo model in eliminating autologous B lymphocytes and, therefore, may be suited for clinical development for lymphoma therapy.
CONFLICT OF INTEREST
FJB, PWHIP, JGJvdW are employees of Genmab, a biotech company that develops therapeutic human monoclonal antibodies, including the CD20 antibody ofatumumab. MP serves as consultant for Genmab. The remaining authors declare no conflicts of interest.
